Clinical trial

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01689246

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-01-01

PhasePHASE3

Study timeline

Study start (unknown)2013-01-01Date precision: month

Registry last updated2018-03-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer's Diseaseunresolved

Interventions

TRx0237 150 mg/dayDRUG

TRx0237 250 mg/dayDRUG

PlaceboDRUG

Sponsors & collaborators

TauRx Therapeutics Ltdlead sponsor

Mapped research locations

SeoulSouth Korea6 SingaporeSingapore4 LondonUnited Kingdom3 TaipeiTaiwan3 MoscowRussia3 WarsawPoland3 Saint PetersburgRussia3 BerlinGermany2 MilanItaly2 RomaItaly2 BucharestRomania2 SofiaBulgaria2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01689246 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.